Biogen (NASDAQ:BIIB) Price Target Increased to $379.00 by Analysts at Royal Bank of Canada
Biogen (NASDAQ:BIIB – Free Report) had its target price hoisted by Royal Bank of Canada from $363.00 to $379.00 in a research note published on Monday morning. The firm currently has an overweight rating on the biotechnology company’s stock. Several other brokerages also recently commented on BIIB. BTIG Research reissued a neutral rating on shares […]
More Stories
US to Release up to 92.5 Million Barrels of Oil From Reserves
By Naveen Athrappully The United States is considering releasing up to 92.5 million barrels of crude oil from its Strategic...
Pentagon Forges Partnership With Leading AI Companies
By Stacy Robinson The Pentagon has entered into an alliance with seven leading artificial intelligence (AI) companies, the Department of...
Chevron, Exxon Decline to Boost Oil Production Despite Trump Admin Requests
By Guy Birchall ExxonMobil and Chevron have said they won’t boost oil production despite the Trump administration’s calls for them...
Trump Announces New 25 Percent Tariff on Cars and Trucks From EU
By Jack Phillips President Donald Trump announced Friday that he will increase the tariffs on cars and trucks imported from...
US Treasury Warns Ships Not to Pay Strait of Hormuz Tolls to Iran
By Jack Phillips The Treasury Department on Friday warned it will impose sanctions on ships that pay a toll to...
Who is Allie Rebelo? And Her Relationship With Justin and Hailey Bieber
Have you also seen Allie Rebelo video on TikTok? And now wants to know about who is Allie Bieber and...